EP0718289B1 — Novel parabanic acid derivatives as aldose reductase inhibitors
Assigned to Nippon Zoki Pharmaceutical Co Ltd · Expires 2003-03-05 · 23y expired
What this patent protects
A compound is provided represented by the following general formula (I) <CHEM> In the formula, R is hydrogen, C1-4 alkyl or benzyl; X is phenyl which is substituted with trifluoromethyl, cyano, carboxy, carbamoyl, C1-3 alkoxycarbonyl or both nitro and halogen, benzothi…
USPTO Abstract
A compound is provided represented by the following general formula (I) <CHEM> In the formula, R is hydrogen, C1-4 alkyl or benzyl; X is phenyl which is substituted with trifluoromethyl, cyano, carboxy, carbamoyl, C1-3 alkoxycarbonyl or both nitro and halogen, benzothiazolyl which may be substituted with C1-3 alkyl, C1-3 alkoxy, trifluoromethyl, nitro and/or halogen, naphthyl which may be substituted with nitro and/or halogen, pyridyl which may be substituted with nitro and/or halogen, anthraquinonyl, phthalimide, or thienyl; and n is an integer from 1 to 3. The compounds act as selective inhibitors of aldose reductase. The compounds provided are useful as drugs for therapy and prevention of various types of diabetic complications.
Drugs covered by this patent
- Tryvio (APROCITENTAN) · Idorsia
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.